Skip to content Skip to footer
VIEWPOINTS_Michael Irizarry_2023

Michael Irizarry shares insights from the P-III clinical study of LEQEMBI, for the treatment of Alzheimer’s disease

Shots:Michael Irizarry, Senior VP of Clinical Research and Deputy Chief Clinical Officer, Alzheimer’s Disease and Brain Health at Eisai in a stimulating conversation with PharmaShotsMichael shares insights from the P-III clinical study Clarity AD of LEQEMBI for the treatment of Alzheimer’s diseaseThe study highlights that LEQEMBI treatment met the primary endpoint and…

Read more

PharmaShots Interview In Conversation with Four Prominent Leaders from Eisai Where they Share Insights on New Alzheimer’s Data Presented at the Alzheimer’s & Parkinson’s Disease Conference

PharmaShots Interview: In Conversation with Four Prominent Leaders* from Eisai Where they Share Insights on New Alzheimer’s Data Presented at the Alzheimer’s & Parkinson’s Disease Conference

Shots:The interview provided an understanding of the data from its Alzheimer’s disease pipeline at the AD/PD ConferenceThe spokespeople also talked about the clinical trial data and key mechanisms of Eisai’s anti-amyloid compound in AD The discussion showed gave a gist of four key symposium presentations that showed how its lead candidate has the…

Read more

PharmaShots Interview: Clario’s Joyce Suhy Shares Insights on PET Imaging Clinical Trials

In an interview with PharmaShots, Joyce Suhy, Senior Vice President, Medical Imaging at Clario shares her views on the PET imaging clinical trials & expands its 2018 collaboration with XingImaging for Alzheimer’s disease and other neurodegenerative diseasesShots:Clario & XingImaging have expanded the collaboration to provide PET imaging clinical trials for neurodegenerative therapeutics in China. The initial study used Amyvid (florbetapir) PET imaging to…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]